Literature DB >> 14695144

Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion.

Georg Sauer1, Jasmin Windisch, Christian Kurzeder, Volker Heilmann, Rolf Kreienberg, Helmut Deissler.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: Lymphovascular space invasion plays a critical role in the progression of cervical cancer and is an indicator of an unfavorable prognosis, even in patients with early-stage disease. Identification and functional characterization of molecules that are predominantly expressed in tumors able to penetrate lymphatic vessels may therefore help to improve the clinical assessment of cervical neoplasias with unclear prognosis. We used immunohistochemical staining to assess expression of the tetraspanin adapter protein CD9 in cervical tumors because inverse correlations with tumor invasiveness, ability to form metastases, and poor clinical outcome have been described for several other tumor types. RESULTS AND
CONCLUSION: We found that CD9, strongly expressed by cells forming the basal layer of normal squamous epithelium of the cervix, is down-regulated in most invasive cervical carcinomas (correlation with stage, P = 0.015) but apparently re-expressed at distinct regions during tumor progression. Tumor sites with pronounced localized expression of CD9 (CD9 hotspots) include cones growing into blood or lymphatic vessels, pointing to a functional role of CD9 in transendothelial migration as a crucial step in the formation of lymph node metastases. Remarkably, CD9 hotspots were found to be a highly significant (P < 10(-5)) indicator of lymphangiosis: they were observed in 15 of 18 cases with histopathologically confirmed lymphangiosis compared with 4 of 26 other cervical carcinomas. We postulate, therefore, that clusters of tumor cells characterized by strong expression of CD9 may be useful as an indicator of high risk of recurrence in early-stage cervical cancer, providing a basis for clinical decisions in favor of additional treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695144

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Immunohistochemical distribution of the tetraspanin CD9 in normal porcine tissues.

Authors:  Noemí Yubero; Angeles Jiménez-Marín; Concepción Lucena; Manuel Barbancho; Juan J Garrido
Journal:  Mol Biol Rep       Date:  2010-06-29       Impact factor: 2.316

Review 2.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

3.  Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.

Authors:  Dorothee Pflueger; Stéphane Terry; Andrea Sboner; Lukas Habegger; Raquel Esgueva; Pei-Chun Lin; Maria A Svensson; Naoki Kitabayashi; Benjamin J Moss; Theresa Y MacDonald; Xuhong Cao; Terrence Barrette; Ashutosh K Tewari; Mark S Chee; Arul M Chinnaiyan; David S Rickman; Francesca Demichelis; Mark B Gerstein; Mark A Rubin
Journal:  Genome Res       Date:  2010-10-29       Impact factor: 9.043

Review 4.  Tetraspanins: push and pull in suppressing and promoting metastasis.

Authors:  Margot Zöller
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 5.  Tetraspanin proteins promote multiple cancer stages.

Authors:  Martin E Hemler
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

6.  Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.

Authors:  Yu Shi; Wenchao Zhou; Lin Cheng; Cong Chen; Zhi Huang; Xiaoguang Fang; Qiulian Wu; Zhicheng He; Senlin Xu; Justin D Lathia; Yifang Ping; Jeremy N Rich; Xiu-Wu Bian; Shideng Bao
Journal:  Cell Death Differ       Date:  2016-10-14       Impact factor: 15.828

7.  The Impact of the CD9 Tetraspanin on Lentivirus Infectivity and Exosome Secretion.

Authors:  Kai O Böker; Nicolas Lemus-Diaz; Rafael Rinaldi Ferreira; Lara Schiller; Stefan Schneider; Jens Gruber
Journal:  Mol Ther       Date:  2017-11-16       Impact factor: 11.454

8.  Differential expression of tetraspanin CD9 in basal cell and squamous cell carcinomas of the skin and actinic keratosis.

Authors:  Thomas Ach; Mirjana Ziemer; Jens Dawczynski; Jürgen Strobel; Georg Sauer; Helmut Deissler
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 9.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

10.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.